MX2008000984A - Metodos para reducir la carga viral en pacientes infectados con vih-1. - Google Patents
Metodos para reducir la carga viral en pacientes infectados con vih-1.Info
- Publication number
- MX2008000984A MX2008000984A MX2008000984A MX2008000984A MX2008000984A MX 2008000984 A MX2008000984 A MX 2008000984A MX 2008000984 A MX2008000984 A MX 2008000984A MX 2008000984 A MX2008000984 A MX 2008000984A MX 2008000984 A MX2008000984 A MX 2008000984A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- hiv
- subject
- viral load
- ccr5
- Prior art date
Links
- 230000003612 virological effect Effects 0.000 title abstract 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 abstract 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 102000004274 CCR5 Receptors Human genes 0.000 abstract 1
- 108010017088 CCR5 Receptors Proteins 0.000 abstract 1
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229940121292 leronlimab Drugs 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Marine Sciences & Fisheries (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
Abstract
La presente invencion se refiere a un metodo para reducir la carga viral VIH-1 en un sujeto humano infectado con VIH-1, el cual comprende administrar al sujeto, a un intervalo predefinido efectivo, dosis que reducen la carga viral VIH-1 de (a) un anticuerpo humanizado designado PRO 140, o de (b) un anticuerpo monoclonal del receptor anti-CCR5. Esta invencion tambien proporciona un metodo para inhibir en un sujeto humano, el comienzo o progreso de un trastorno asociado con VIH-1, la inhibicion del cual es efectuada inhibiendo la fusion de VIH-1 a celulas objetivo CD4+ CD5+ en el sujeto. Esta invencion tambien proporciona un metodo para tratar un sujeto infectado con VIH que comprende, administrar al sujeto (a) un anticuerpo monoclonal el cual (i) se enlaza a un receptor CCR5 en la superficie de las celulas CD4+ del sujeto y (ii) inhibe la fusion del VIH-1 a las celulas CD4+ CCR5+ del sujeto, y (b) un antagonista del receptor CCR5 sin anticuerpo, en cantidades efectivas para tratar al sujeto.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70206405P | 2005-07-22 | 2005-07-22 | |
US70188905P | 2005-07-23 | 2005-07-23 | |
US71152805P | 2005-08-26 | 2005-08-26 | |
US71561905P | 2005-09-09 | 2005-09-09 | |
PCT/US2006/028565 WO2007014114A2 (en) | 2005-07-22 | 2006-07-21 | Methods for reducing viral load in hiv-1-infected patients |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008000984A true MX2008000984A (es) | 2008-04-04 |
Family
ID=37683857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008000984A MX2008000984A (es) | 2005-07-22 | 2006-07-21 | Metodos para reducir la carga viral en pacientes infectados con vih-1. |
Country Status (12)
Country | Link |
---|---|
US (4) | US20070026441A1 (es) |
EP (1) | EP1910573B1 (es) |
JP (1) | JP2009514790A (es) |
KR (1) | KR20080035653A (es) |
AU (1) | AU2006272750B2 (es) |
CA (1) | CA2616189C (es) |
ES (1) | ES2438019T3 (es) |
IL (1) | IL188766A0 (es) |
MX (1) | MX2008000984A (es) |
NO (1) | NO20080919L (es) |
WO (1) | WO2007014114A2 (es) |
ZA (1) | ZA200800641B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6261763B1 (en) | 1995-06-07 | 2001-07-17 | Progenics Pharmaceuticals, Inc. | Fluorescence resonance energy transfer screening assay for the identification of compounds that are capable of abrogating macrophage-tropic HIV-1 cell fusion |
US7118859B2 (en) * | 1996-01-17 | 2006-10-10 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
US7858298B1 (en) * | 1996-04-01 | 2010-12-28 | Progenics Pharmaceuticals Inc. | Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists |
US6344545B1 (en) * | 1996-06-14 | 2002-02-05 | Progenics Pharmaceuticals, Inc. | Method for preventing HIV-1 infection of CD4+ cells |
US20040228869A1 (en) * | 1998-12-16 | 2004-11-18 | Progenics Pharmaceuticals, Inc. | Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto |
US7138119B2 (en) * | 2000-09-15 | 2006-11-21 | Progenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
US7060273B2 (en) * | 2001-04-06 | 2006-06-13 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
US7122185B2 (en) * | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
CN105596356A (zh) * | 2003-01-14 | 2016-05-25 | 吉里德科学公司 | 用于联合抗病毒治疗的组合物和方法 |
AU2006272750B2 (en) * | 2005-07-22 | 2011-09-29 | Cytodyn, Inc. | Methods for reducing viral load in HIV-1-infected patients |
WO2007045280A1 (en) * | 2005-10-17 | 2007-04-26 | Telefonaktiebolaget Lm Ericsson (Publ.) | Method for performing handoff in a packet-switched cellular communications system |
EP2150817A4 (en) * | 2007-04-30 | 2011-09-07 | Progenics Pharm Inc | PROCEDURE FOR REDUCING VIRUS LOAD IN HIV-1 INFECTED PATIENTS |
WO2009014638A2 (en) * | 2007-07-19 | 2009-01-29 | Progenics Pharmaceuticals, Inc. | Methods of inhibiting infection by diverse subtypes of drug-resistant hiv-1 |
US20090074766A1 (en) * | 2007-09-14 | 2009-03-19 | Ketas Thomas J | Methods of inhibiting HIV-2 infection |
WO2009134401A2 (en) * | 2008-04-29 | 2009-11-05 | Progenics Pharmaceuticals, Inc. | Methods of inhibiting infection by diverse subtypes of drug-resistant hiv-1 |
US10500274B2 (en) * | 2008-04-30 | 2019-12-10 | Cytodyn Inc. | Methods for reducing viral load in HIV-1 infected patients |
US20110318360A1 (en) * | 2008-09-05 | 2011-12-29 | Duke University | Anti-lipid antibodies |
WO2010142037A1 (en) * | 2009-06-08 | 2010-12-16 | The University Of Western Ontario | An electrochemical method and apparatus of identifying the presence of a target |
SG184176A1 (en) * | 2010-04-02 | 2012-10-30 | Phivco 1 Llc | Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer |
JP2013032241A (ja) | 2011-08-01 | 2013-02-14 | Sumitomo Electric Ind Ltd | 光ファイバ母材製造方法 |
WO2015126892A1 (en) * | 2014-02-18 | 2015-08-27 | Cytodyn Inc | Use of anti-ccr5 antibodies in graft versus host disease |
CN107847514A (zh) * | 2015-06-23 | 2018-03-27 | 西托戴恩股份有限公司 | 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变 |
WO2018039521A1 (en) * | 2016-08-26 | 2018-03-01 | Concert Pharmaceuticals, Inc. | Deuterated cenicriviroc |
CN111201034A (zh) | 2017-05-11 | 2020-05-26 | 西托戴恩股份有限公司 | 涉及施用抗ccr5受体试剂的治疗或预防移植物抗宿主病的方法 |
CN110831436A (zh) | 2017-05-11 | 2020-02-21 | 西托戴恩股份有限公司 | 人源化的小鼠模型 |
CA3089848A1 (en) | 2017-09-18 | 2019-03-21 | Cytodyn Inc. | Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapy |
MX2022001411A (es) | 2019-08-02 | 2022-03-25 | Cytodyn Inc | Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5. |
US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5567610A (en) * | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) * | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
IT1229514B (it) * | 1989-01-30 | 1991-09-03 | Farmhispania S A A Montme | Glicoconiugati anfifilici sintetici per impiego neurologico. |
US5026154A (en) * | 1989-10-06 | 1991-06-25 | The United States Of America As Represented By The United States Department Of Energy | Multipulsed dynamic moire interferometer |
US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5229275A (en) * | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US20030187247A1 (en) * | 1992-09-30 | 2003-10-02 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to human immunodeficiency virus |
US5817767A (en) | 1993-02-24 | 1998-10-06 | Progenics Pharmaceuticals, Inc. | Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same |
AU695565B2 (en) | 1993-12-17 | 1998-08-13 | Progenics Pharmaceuticals, Inc. | Methods for using resonance energy transfer-based assay of HIV-1 envelope glycoprotein-mediated membrane fusion, and kits for practicing same |
EP1148126A3 (en) | 1995-06-06 | 2003-12-03 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HDGNR10 (CCR5 receptor) |
MX9709849A (es) | 1995-06-06 | 1998-03-29 | Human Genome Sciences Inc | Receptor de quimiocina de la proteina g humana o hdgnr10. |
JPH10510719A (ja) | 1995-06-06 | 1998-10-20 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | ヒトgタンパク質ケモカインレセプターhdgnr10 |
US6025154A (en) * | 1995-06-06 | 2000-02-15 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor HDGNR10 |
US6261763B1 (en) * | 1995-06-07 | 2001-07-17 | Progenics Pharmaceuticals, Inc. | Fluorescence resonance energy transfer screening assay for the identification of compounds that are capable of abrogating macrophage-tropic HIV-1 cell fusion |
US6265184B1 (en) * | 1995-12-20 | 2001-07-24 | Icos Corporation | Polynucleotides encoding chemokine receptor 88C |
US7118859B2 (en) * | 1996-01-17 | 2006-10-10 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
AU1750497A (en) | 1996-01-17 | 1997-08-11 | Progenics Pharmaceuticals, Inc. | Compounds capable of inhibiting hiv-1 infection |
WO1997028258A1 (en) | 1996-01-30 | 1997-08-07 | The National Institutes Of Health | Cells expressing both human cd4 and cxcr4 |
EP1482042B1 (en) * | 1996-03-01 | 2009-04-15 | Euroscreen S.A. | Active and inactive CC-chemokine receptors and nucleic acid molecules encoding said receptor |
US6344545B1 (en) * | 1996-06-14 | 2002-02-05 | Progenics Pharmaceuticals, Inc. | Method for preventing HIV-1 infection of CD4+ cells |
US6107019A (en) * | 1996-06-14 | 2000-08-22 | Progenics Pharmaceuticals, Inc. | Method for preventing HIV-1 infection of CD4+ cells |
JP2000507596A (ja) | 1996-04-02 | 2000-06-20 | プロジェニクス・ファーマスーティカルス・インコーポレーテッド | Cd4▲上+▼細胞のhiv―1感染を防ぐ方法 |
US6258527B1 (en) * | 1996-05-20 | 2001-07-10 | The Aaron Diamond Aids Research Center | Methods of identifying g-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof |
US5939320A (en) | 1996-05-20 | 1999-08-17 | New York University | G-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof |
FR2748938B1 (fr) | 1996-05-22 | 1998-07-31 | Pasteur Institut | Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih |
AU3375697A (en) * | 1996-05-28 | 1998-01-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Cc chemokine receptor 5, antibodies thereto, transgenic animals |
WO1997047319A1 (en) | 1996-06-14 | 1997-12-18 | Progenics Pharmaceuticals, Inc. | Uses of a chemokine receptor for inhibiting hiv-1 infection |
US20040086528A1 (en) * | 1996-06-14 | 2004-05-06 | Progenics Pharmaceuticals, Inc. | Uses of a chemokine receptor for inhibiting HIV-1 infection |
US6528625B1 (en) * | 1996-10-28 | 2003-03-04 | Millennium Pharmaceuticals, Inc. | Anti-CCR5 antibodies and kits comprising same |
CA2297825C (en) * | 1997-07-25 | 2006-03-14 | H. Lundbeck A/S | Indole and 2,3-dihydroindole derivatives, their preparation and use |
EP1021723B1 (en) * | 1997-09-22 | 2008-12-10 | Novartis Vaccines and Diagnostics, Inc. | Buffers for stabilizing hcv antigens |
US6100087A (en) * | 1998-03-11 | 2000-08-08 | City Of Hope | Ribozymes targeted to human CCR5 mRNA |
US6258782B1 (en) * | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US20040228869A1 (en) * | 1998-12-16 | 2004-11-18 | Progenics Pharmaceuticals, Inc. | Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto |
US6692745B2 (en) * | 2000-01-28 | 2004-02-17 | Arogenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
WO2001058916A2 (en) * | 2000-02-09 | 2001-08-16 | Human Genome Sciences, Inc. | Antibodies to ccr5 |
US6476034B2 (en) * | 2000-02-22 | 2002-11-05 | Bristol-Myers Squibb Company | Antiviral azaindole derivatives |
US20020061892A1 (en) | 2000-02-22 | 2002-05-23 | Tao Wang | Antiviral azaindole derivatives |
EP1399180A4 (en) * | 2000-02-29 | 2004-04-07 | Progenics Pharm Inc | CCR5 SULPHATE PEPTIDES FOR THE TREATMENT OF HIV-1 INFECTION |
JP3693957B2 (ja) | 2000-05-26 | 2005-09-14 | ファイザー・インク | 療法において有用なトロパン誘導体 |
US7138119B2 (en) | 2000-09-15 | 2006-11-21 | Progenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
US7175988B2 (en) * | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
AU2002255642A1 (en) * | 2001-02-28 | 2002-09-12 | Aaron Diamond Aids Research Centre | Sulfated ccr5 peptides for hiv-1 infection |
US20030003440A1 (en) * | 2001-03-14 | 2003-01-02 | Lucia Lopalco | Novel CCR5 epitope and antibodies against it |
US7060273B2 (en) * | 2001-04-06 | 2006-06-13 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
US20020146415A1 (en) | 2001-04-06 | 2002-10-10 | Olson William C. | Methods for inhibiting HIV-1 infection |
US6825210B2 (en) * | 2001-04-19 | 2004-11-30 | Bristol-Myers Squibb Pharma Company | Tricyclic compounds useful as HIV reverse transcriptase inhibitors |
CA2463931A1 (en) * | 2001-10-16 | 2003-04-24 | The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services | Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes |
US7393934B2 (en) * | 2001-12-21 | 2008-07-01 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor (CCR5) HDGNR10 |
US7122185B2 (en) * | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
CA2476901C (en) * | 2002-02-22 | 2012-10-09 | Progenics Pharmaceuticals, Inc. | Anti-ccr5 antibody |
US6884889B2 (en) | 2002-03-25 | 2005-04-26 | Bristol-Myers Squibb Co. | Processes for the preparation of antiviral 7-azaindole derivatives |
RU2353357C2 (ru) * | 2003-05-16 | 2009-04-27 | Юниверсити Оф Мэрилэнд Байотекнолоджи Инститьют | Композиции для супрессии экспрессии ccr5 и способы их применения |
US20050131042A1 (en) * | 2003-12-11 | 2005-06-16 | Flentge Charles A. | HIV protease inhibiting compounds |
JP2007515965A (ja) * | 2003-12-23 | 2007-06-21 | セントカー・インコーポレーテツド | 抗レトロウイルス性の剤、組成物、方法および用途 |
CA2559809A1 (en) * | 2004-03-12 | 2005-11-10 | Human Genome Sciences, Inc. | Antibodies against human g-protein chemokine receptor (ccr5) hdgnr10 |
AR048650A1 (es) * | 2004-05-04 | 2006-05-10 | Tibotec Pharm Ltd | Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih |
AU2006272750B2 (en) * | 2005-07-22 | 2011-09-29 | Cytodyn, Inc. | Methods for reducing viral load in HIV-1-infected patients |
EP2150817A4 (en) * | 2007-04-30 | 2011-09-07 | Progenics Pharm Inc | PROCEDURE FOR REDUCING VIRUS LOAD IN HIV-1 INFECTED PATIENTS |
-
2006
- 2006-07-21 AU AU2006272750A patent/AU2006272750B2/en not_active Ceased
- 2006-07-21 ES ES06788240.7T patent/ES2438019T3/es active Active
- 2006-07-21 US US11/491,330 patent/US20070026441A1/en not_active Abandoned
- 2006-07-21 KR KR1020087004340A patent/KR20080035653A/ko not_active Application Discontinuation
- 2006-07-21 EP EP06788240.7A patent/EP1910573B1/en active Active
- 2006-07-21 JP JP2008523029A patent/JP2009514790A/ja not_active Withdrawn
- 2006-07-21 CA CA2616189A patent/CA2616189C/en not_active Expired - Fee Related
- 2006-07-21 WO PCT/US2006/028565 patent/WO2007014114A2/en active Search and Examination
- 2006-07-21 MX MX2008000984A patent/MX2008000984A/es not_active Application Discontinuation
-
2007
- 2007-08-20 US US11/894,762 patent/US20080241135A1/en not_active Abandoned
-
2008
- 2008-01-14 IL IL188766A patent/IL188766A0/en unknown
- 2008-01-22 ZA ZA2008/00641A patent/ZA200800641B/en unknown
- 2008-02-22 NO NO20080919A patent/NO20080919L/no not_active Application Discontinuation
-
2010
- 2010-11-24 US US12/954,464 patent/US8821877B2/en active Active
-
2014
- 2014-06-30 US US14/319,505 patent/US20140377259A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2006272750A1 (en) | 2007-02-01 |
JP2009514790A (ja) | 2009-04-09 |
KR20080035653A (ko) | 2008-04-23 |
EP1910573B1 (en) | 2013-09-04 |
ZA200800641B (en) | 2011-11-30 |
US20070026441A1 (en) | 2007-02-01 |
EP1910573A4 (en) | 2010-04-07 |
US20140377259A1 (en) | 2014-12-25 |
US8821877B2 (en) | 2014-09-02 |
US20080241135A1 (en) | 2008-10-02 |
US20110200592A1 (en) | 2011-08-18 |
CA2616189A1 (en) | 2007-02-01 |
CA2616189C (en) | 2019-03-26 |
WO2007014114A3 (en) | 2009-01-08 |
IL188766A0 (en) | 2008-08-07 |
AU2006272750B2 (en) | 2011-09-29 |
NO20080919L (no) | 2008-04-22 |
WO2007014114A2 (en) | 2007-02-01 |
ES2438019T3 (es) | 2014-01-15 |
EP1910573A2 (en) | 2008-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2008000984A (es) | Metodos para reducir la carga viral en pacientes infectados con vih-1. | |
SG148143A1 (en) | Antagonist anti-cd40 monoclonal antibodies and methods for their use | |
JP2019525957A5 (es) | ||
US20200069797A1 (en) | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists | |
JP2014530226A5 (es) | ||
WO2005044855A3 (en) | Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma | |
WO2015081158A1 (en) | Method of treating hiv by disrupting pd-1/pd-l1 signaling | |
MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
SI2766039T1 (en) | Ingredients for the treatment of rheumatoid arthritis and procedures for their use | |
ATE327004T1 (de) | Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40 | |
DK1682177T3 (da) | Anvendelse af antagonist-anti-CD40-antistoffer til behandling af kronisk lymfocytisk leukæmi | |
RU2019106804A (ru) | Лечение и устойчивая вирусологическая ремиссия при вич-инфекции у haart-стабилизированных пациентов с помощью антител против cd4 | |
Sharma et al. | An anti-inflammatory role of VEGFR2/Src kinase inhibitor in herpes simplex virus 1-induced immunopathology | |
RU2014134923A (ru) | Антагонисты alk1 и их применение в лечении почечно-клеточного рака | |
WO2013024155A1 (en) | Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection | |
RU2010126598A (ru) | Применение человеческого антитела, способного нейтрализовать вирус гепатита в, для профилактики или лечения инфекции вирусом гепатита в | |
Potts et al. | Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies | |
RU2017112967A (ru) | Лечение и функциональное излучение вич-инфекции моноклональными антителами к cd4, опосредующими конкуретное ингибирование входа вич | |
MX2023001734A (es) | Métodos para prevenir y tratar la disfunción cardíaca y el covid-19 con antagonistas de activina a. | |
MX2022005443A (es) | Terapia con células t car dirigidas a bcma contra el mieloma múltiple. | |
MX2022001411A (es) | Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5. | |
JPWO2014189138A1 (ja) | 免疫不全ウイルス感染の治療又は予防剤 | |
Ibtehaj et al. | B cell-specific mAb–siRNA conjugates improve experimental myasthenia | |
Carbone | C-105 Lymphomas and other cancers in HIV-infected patients | |
WO2009014638A3 (en) | Methods of inhibiting infection by diverse subtypes of drug-resistant hiv-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |